Overall, these findings suggest that long-term cardiovascular outcomes in revascularized heart failure patients are primarily determined by individual patient characteristics—such as age, cardiac rhythm status, and comorbidity burden—rather than the specific SGLT2 inhibitor prescribed. This evidence concerns the gene SLC5A2 and heart failure.